Ascorbate Biosynthesis: A cross-kingdom history
Between two and three billion years ago, living things evolved the ability to use oxygen to increase the amount of energy that could be released from carbon-rich molecules. However, these reactions produce harmful molecules called ‘reactive oxygen species’ as by-products, so antioxidant systems had to be developed in parallel to detoxify them (Noctor and Foyer, 1998; Gest et al., 2013).
A compound called ascorbate is an excellent antioxidant that is made by almost all living organisms. However, certain animals—including guinea pigs (Nishikimi et al., 1992), most bats, some fish and bird species, as well as humans and many other primates—have all have lost the ability to synthesise this compound for themselves (Mandl et al., 2009). Instead, these animals must obtain ascorbate (which is also known as ‘vitamin C’) from their diets. Moreover, all of these animals are unable to make ascorbate for the same reason: they have all lost a gene that encodes an enzyme called gulonolactone oxidase (or GULO). This enzyme catalyses the final step in the metabolic pathway that produces ascorbate in other animals.
Three major routes of ascorbate biosynthesis have been described across the kingdoms of life. The animal kingdom uses one of these pathways, and photosynthetic eukaryotes—such as plants, algae and some single-celled organisms—employ the other two. All three pathways proceed via different intermediate molecules, but the two from photosynthetic eukaryotes both use an enzyme called galactolactone dehydrogenase (or GLDH), instead of GULO, to catalyse the final step (Wheeler et al., 1998).
Now, in eLife, Glen Wheeler (Marine Biological Association), Takahiro Ishikawa (Shimane University), and Varissa Pornsaksit and Nicholas Smirnoff (both at the University of Exeter) have analysed the distribution of these two enzymes amongst the genomes of many different eukaryotes to determine the origins of ascorbate biosynthesis (Wheeler et al., 2015). They found that each genome either contained a gene for GULO or a gene for GLDH, but not both (Figure 1A). They also revealed that the ancestor of all animals and fungi (and their close relatives) likely used GULO, and that this ancestral trait has been lost in many later groups, including all insects.
Ascorbate biosynthesis via GULO also occurs in several other groups of eukaryotes, including a primitive, freshwater alga called Cyanophora paradoxa and two species in a single genus of red algae (called Galdieria). However, the gene for GULO is absent in the genomes of the vast majority of other algae and the land plants. Instead, Wheeler et al. revealed that almost all photosynthetic eukaryotes use the GLDH enzyme. Gene expression datasets confirmed that this enzyme is also found in non-photosynthetic organisms that are descended from photosynthetic ancestors—namely the water moulds (or oomycetes). Moreover, while several non-photosynthetic organisms (including the ciliates and an amboebozoan) lacked both genes, this was not the case for any photosynthetic eukaryote.
Wheeler et al. also provide strong evidence that the genes for GULO and GLDH have each only arisen once—and other evidence suggests that it is possible that the two enzymes are originally descended from a single gene. This implies two possible scenarios. Firstly, GULO and GLDH could result from a single gene that was duplicated in the last common ancestor of all eukaryotes, and different lineages have subsequently lost either one gene or the other. Secondly, the two genes might have evolved in different lineages and passed between species via ‘horizontal gene transfer’. However, whilst compelling arguments are put forward for both cases, it is not currently possible to exclude either of these explanations or, indeed, a combination of both in different lineages.
Nevertheless, their comprehensive analyses allowed Wheeler et al. to speculate on the selective pressures that might have driven the evolutionary path of ascorbate biosynthesis in eukaryotes (Figure 1B). Reactive oxygen species are produced when energy from sunlight is harvested during photosynthesis. This means that photosynthetic organisms experience ‘photo-oxidative stress’ and need more efficient antioxidant systems. As such, Wheeler et al. put forward an attractive hypothesis that GULO was lost in eukaryotes that became photosynthetic because this enzyme also produces some reactive oxygen species (namely hydrogen peroxide). Photosynthetic eukaryotes switched to use GLDH instead because this enzyme can synthesise ascorbate without producing reactive oxygen species as by-products. The fact that the Galdieria red algae have retained GULO can also be explained since it grows on or inside porous rocks in hot sulphur springs where photo-oxidative stress is believed to be minimal.
Studying other enzymes involved in the ascorbate antioxidant system revealed that C. paradoxa is the only photosynthetic organism to lack these enzymes. However, photosynthetic bacteria (i.e., cyanobacteria) don't appear to use ascorbate to protect against photo-oxidative stress. This suggests that the ‘photoprotective’ role of ascorbate may have emerged in photosynthetic eukaryotes after C. paradoxa (and other glaucophytes) diverged from the lineages that went on to be come the red algae, the green algae and the land plants.
Finally, the evolution of a photoprotective role of ascorbate would have increased the amount of this compound found in the leaves of land plants. As such the loss of GULO in several animal lineages may well reflect the increased availability of ascorbate in their largely plant-based diets.
Wheeler et al. thus provide major insight into the evolution of ascorbate metabolism in eukaryotes. In addition, when taken together with recent studies concerning the evolution of other antioxidants (Tohge et al., 2013) and plant hormones (Ju et al., 2015), the enormous potential resulting from the torrent of information provided by modern genome sequencing technologies becomes apparent (Tautz et al., 2010). In the coming years, one can anticipate that the widespread adoption of similar approaches will enable a far greater understanding of the evolution of both fundamental and specialised metabolic pathways in all kingdoms of life.
References
-
Ascrobate as seen through plant evolution: the rise of a successful molecule?Journal of Experimental Botany 64:33–53.https://doi.org/10.1093/jxb/ers297
-
Vitamin C: update on physiology and pharmacologyBritish Journal of Pharmacology 157:1097–1110.https://doi.org/10.1111/j.1476-5381.2009.00282.x
-
Guinea pigs possess a highly mutated gene for L-gulono-gamma-lactone oxidase, the key enzyme for L-ascorbic acid biosynthesis missing in this speciesJournal of Biological Chemistry 267:21967–21972.
-
Ascorbate and glutathione: keeping active oxygen under controlAnnual Review of Plant Physiology and Plant Molecular Biology 49:249–279.https://doi.org/10.1146/annurev.arplant.49.1.249
-
Next generation molecular ecologyMolecular Ecology 19:1–3.https://doi.org/10.1111/j.1365-294X.2009.04489.x
-
The evolution of phenylpropanoid metabolism in the green lineageCritical Reviews in Biochemistry and Molecular Biology 48:123–152.https://doi.org/10.3109/10409238.2012.758083
Article and author information
Author details
Publication history
Copyright
© 2015, Fernie and Tohge
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,464
- views
-
- 232
- downloads
-
- 3
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Evolutionary Biology
With the availability of high-quality full genome polymorphism (SNPs) data, it becomes feasible to study the past demographic and selective history of populations in exquisite detail. However, such inferences still suffer from a lack of statistical resolution for recent, for example bottlenecks, events, and/or for populations with small nucleotide diversity. Additional heritable (epi)genetic markers, such as indels, transposable elements, microsatellites, or cytosine methylation, may provide further, yet untapped, information on the recent past population history. We extend the Sequential Markovian Coalescent (SMC) framework to jointly use SNPs and other hyper-mutable markers. We are able to (1) improve the accuracy of demographic inference in recent times, (2) uncover past demographic events hidden to SNP-based inference methods, and (3) infer the hyper-mutable marker mutation rates under a finite site model. As a proof of principle, we focus on demographic inference in Arabidopsis thaliana using DNA methylation diversity data from 10 European natural accessions. We demonstrate that segregating single methylated polymorphisms (SMPs) satisfy the modeling assumptions of the SMC framework, while differentially methylated regions (DMRs) are not suitable as their length exceeds that of the genomic distance between two recombination events. Combining SNPs and SMPs while accounting for site- and region-level epimutation processes, we provide new estimates of the glacial age bottleneck and post-glacial population expansion of the European A. thaliana population. Our SMC framework readily accounts for a wide range of heritable genomic markers, thus paving the way for next-generation inference of evolutionary history by combining information from several genetic and epigenetic markers.
-
- Computational and Systems Biology
- Evolutionary Biology
There is growing interest in designing multidrug therapies that leverage tradeoffs to combat resistance. Tradeoffs are common in evolution and occur when, for example, resistance to one drug results in sensitivity to another. Major questions remain about the extent to which tradeoffs are reliable, specifically, whether the mutants that provide resistance to a given drug all suffer similar tradeoffs. This question is difficult because the drug-resistant mutants observed in the clinic, and even those evolved in controlled laboratory settings, are often biased towards those that provide large fitness benefits. Thus, the mutations (and mechanisms) that provide drug resistance may be more diverse than current data suggests. Here, we perform evolution experiments utilizing lineage-tracking to capture a fuller spectrum of mutations that give yeast cells a fitness advantage in fluconazole, a common antifungal drug. We then quantify fitness tradeoffs for each of 774 evolved mutants across 12 environments, finding these mutants group into classes with characteristically different tradeoffs. Their unique tradeoffs may imply that each group of mutants affects fitness through different underlying mechanisms. Some of the groupings we find are surprising. For example, we find some mutants that resist single drugs do not resist their combination, while others do. And some mutants to the same gene have different tradeoffs than others. These findings, on one hand, demonstrate the difficulty in relying on consistent or intuitive tradeoffs when designing multidrug treatments. On the other hand, by demonstrating that hundreds of adaptive mutations can be reduced to a few groups with characteristic tradeoffs, our findings may yet empower multidrug strategies that leverage tradeoffs to combat resistance. More generally speaking, by grouping mutants that likely affect fitness through similar underlying mechanisms, our work guides efforts to map the phenotypic effects of mutation.